Antibody therapies for the prevention and treatment of viral infections

Abstract

Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.

Cited by papers we hold 4

• New insights into protein–protein interaction modulators in drug discovery and therapeutic advance · 2024
  No notice
• Early diagnosis and successful treatment of cytomegalovirus peritonitis in children with primary nephrotic syndrome: case series and literature review · 2020
  Not checked
• Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike · 2020
  Corrected
• Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.